Kintara Therapeutics (KTRA)
(Delayed Data from NSDQ)
$0.29 USD
+0.02 (6.04%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.29 0.00 (0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Kintara Therapeutics, Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 2 | 12 | 11 | 2 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 1 | 1 | 0 |
Total Current Assets | NA | 3 | 13 | 12 | 3 |
Net Property & Equipment | NA | 1 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 3 | 2 | 0 |
Total Assets | NA | 4 | 16 | 14 | 3 |
Liabilities & Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 3 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 1 | 1 |
Total Current Liabilities | NA | 3 | 4 | 3 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 3 | 4 | 3 | 3 |
Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 11 | 13 | 15 | 5 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 141 | 136 | 107 | 57 |
Retained Earnings | NA | -151 | -136 | -111 | -70 |
Other Equity | NA | 0 | 0 | 0 | 9 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 1 | 12 | 11 | 0 |
Total Liabilities & Shareholder's Equity | NA | 4 | 16 | 14 | 3 |
Total Common Equity | 0 | -10 | -1 | -4 | -5 |
Shares Outstanding | 55.30 | 1.60 | 1.30 | 0.60 | 0.20 |
Book Value Per Share | 0.00 | -6.20 | -0.58 | -7.25 | -22.70 |
Fiscal Year End for Kintara Therapeutics, Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 6 | 1 | 0 | 2 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 1 | 2 |
Total Current Assets | NA | 7 | 1 | 1 | 3 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 7 | 2 | 1 | 4 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 2 | 3 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 1 | 2 | 3 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 2 | 2 | 4 | 3 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 10 | 10 | 11 | 11 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 153 | 145 | 142 | 141 |
Retained Earnings | NA | -158 | -156 | -155 | -151 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 6 | 0 | -2 | 1 |
Total Liabilities & Shareholder's Equity | NA | 7 | 2 | 1 | 4 |
Total Common Equity | 0 | -4 | -10 | -13 | -10 |
Shares Outstanding | 55.30 | 55.30 | 10.10 | 1.70 | 1.60 |
Book Value Per Share | 0.00 | -0.08 | -1.03 | -7.44 | -6.20 |